Full Text View
Tabular View
No Study Results Posted
Related Studies
Safety and Efficacy of LCI699 in Cushing's Disease Patients
This study is currently recruiting participants.
Verified April 2013 by Novartis
Study NCT01331239   Information provided by Novartis

First Received on April 6, 2011.   Last Updated on April 5, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Cushing's Disease
Additional conditions recognized in this trial
Cushing Syndrome
Pituitary ACTH Hypersecretion
More general conditions related to this trial
Adrenal Gland Diseases
Adrenocortical Hyperfunction
Brain Diseases
Central Nervous System Diseases
Endocrine System Diseases
Hyperpituitarism
Hypothalamic Diseases
Nervous System Diseases
Pituitary Diseases
Interventions listed in this trial
LCI699
Additional drug interventions recognized in this trial
Adrenocorticotropic Hormone
More general drug interventions related to this trial
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Pharmacologic Actions
Physiological Effects of Drugs
Sponsors listed in this trial
Novartis Pharmaceuticals


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services